Different infusion durations for preventing platinum-induced hearing loss in children with cancer

  • Protocol
  • Intervention

Authors

  • Jorrit W van As,

    Corresponding author
    1. Emma Children's Hospital / Academic Medical Center, c/o Cochrane Childhood Cancer Group, Amsterdam, Netherlands
    • Jorrit W van As, c/o Cochrane Childhood Cancer Group, Emma Children's Hospital / Academic Medical Center, PO Box 22660, Amsterdam, 1100 DD, Netherlands. Jorritvas@gmail.com.

    Search for more papers by this author
  • Henk van den Berg,

    1. Emma Children's Hospital / Academic Medical Center, Department of Paediatric Oncology, Amsterdam, Netherlands
    Search for more papers by this author
  • Elvira C van Dalen

    1. Emma Children's Hospital / Academic Medical Center, Department of Paediatric Oncology, Amsterdam, Netherlands
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effects of any platinum infusion duration to prevent hearing loss and/or tinnitus in children with cancer treated with platinum-based therapy (i.e. including cisplatin, carboplatin and/or oxaliplatin) when compared to another infusion duration. We will also assess possible effects of these infusion durations on anti-tumour efficacy (i.e. tumour response and survival) of platinum-based therapy, on adverse effects other than hearing loss and/or tinnitus and on quality of life.